Intrinsic value of Akebia Therapeutics, Inc. - AKBA

Previous Close

$4.10

  Intrinsic Value

$0.25

stock screener

  Rating & Target

str. sell

-94%

Previous close

$4.10

 
Intrinsic value

$0.25

 
Up/down potential

-94%

 
Rating

str. sell

We calculate the intrinsic value of AKBA stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.5

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  28.80
  26.42
  24.28
  22.35
  20.62
  19.05
  17.65
  16.38
  15.25
  14.22
  13.30
  12.47
  11.72
  11.05
  10.44
  9.90
  9.41
  8.97
  8.57
  8.22
  7.89
  7.60
  7.34
  7.11
  6.90
  6.71
  6.54
  6.38
  6.25
  6.12
Revenue, $m
  229
  290
  360
  441
  532
  633
  745
  867
  999
  1,141
  1,292
  1,453
  1,624
  1,803
  1,992
  2,189
  2,395
  2,609
  2,833
  3,066
  3,308
  3,559
  3,821
  4,093
  4,375
  4,668
  4,974
  5,291
  5,621
  5,966
Variable operating expenses, $m
  4,122
  5,210
  6,475
  7,922
  9,556
  11,376
  13,384
  15,577
  17,951
  20,504
  23,230
  26,127
  29,189
  32,414
  35,800
  39,344
  43,047
  46,907
  50,929
  55,112
  59,463
  63,984
  68,683
  73,566
  78,641
  83,917
  89,403
  95,110
  101,051
  107,236
Fixed operating expenses, $m
  114
  117
  120
  122
  125
  128
  130
  133
  136
  139
  142
  145
  149
  152
  155
  159
  162
  166
  169
  173
  177
  181
  185
  189
  193
  197
  202
  206
  211
  215
Total operating expenses, $m
  4,236
  5,327
  6,595
  8,044
  9,681
  11,504
  13,514
  15,710
  18,087
  20,643
  23,372
  26,272
  29,338
  32,566
  35,955
  39,503
  43,209
  47,073
  51,098
  55,285
  59,640
  64,165
  68,868
  73,755
  78,834
  84,114
  89,605
  95,316
  101,262
  107,451
Operating income, $m
  -4,007
  -5,038
  -6,235
  -7,604
  -9,149
  -10,871
  -12,770
  -14,843
  -17,089
  -19,502
  -22,080
  -24,819
  -27,714
  -30,763
  -33,964
  -37,314
  -40,814
  -44,464
  -48,265
  -52,219
  -56,332
  -60,606
  -65,047
  -69,662
  -74,459
  -79,446
  -84,631
  -90,025
  -95,640
  -101,485
EBITDA, $m
  -4,006
  -5,036
  -6,233
  -7,602
  -9,147
  -10,868
  -12,767
  -14,840
  -17,085
  -19,498
  -22,076
  -24,814
  -27,708
  -30,757
  -33,957
  -37,307
  -40,806
  -44,455
  -48,255
  -52,209
  -56,320
  -60,593
  -65,034
  -69,648
  -74,444
  -79,430
  -84,614
  -90,007
  -95,620
  -101,465
Interest expense (income), $m
  0
  0
  -1
  2
  5
  10
  14
  19
  25
  31
  38
  45
  53
  61
  70
  79
  89
  99
  110
  121
  132
  144
  156
  169
  183
  197
  211
  226
  242
  258
  275
Earnings before tax, $m
  -4,007
  -5,036
  -6,236
  -7,609
  -9,158
  -10,885
  -12,789
  -14,868
  -17,120
  -19,541
  -22,125
  -24,872
  -27,775
  -30,833
  -34,043
  -37,403
  -40,913
  -44,573
  -48,385
  -52,352
  -56,476
  -60,762
  -65,216
  -69,845
  -74,656
  -79,657
  -84,857
  -90,267
  -95,897
  -101,760
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -4,007
  -5,036
  -6,236
  -7,609
  -9,158
  -10,885
  -12,789
  -14,868
  -17,120
  -19,541
  -22,125
  -24,872
  -27,775
  -30,833
  -34,043
  -37,403
  -40,913
  -44,573
  -48,385
  -52,352
  -56,476
  -60,762
  -65,216
  -69,845
  -74,656
  -79,657
  -84,857
  -90,267
  -95,897
  -101,760

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  242
  305
  380
  464
  560
  667
  785
  913
  1,052
  1,202
  1,362
  1,532
  1,711
  1,900
  2,099
  2,306
  2,523
  2,750
  2,985
  3,231
  3,486
  3,751
  4,026
  4,312
  4,610
  4,919
  5,241
  5,575
  5,924
  6,286
Adjusted assets (=assets-cash), $m
  242
  305
  380
  464
  560
  667
  785
  913
  1,052
  1,202
  1,362
  1,532
  1,711
  1,900
  2,099
  2,306
  2,523
  2,750
  2,985
  3,231
  3,486
  3,751
  4,026
  4,312
  4,610
  4,919
  5,241
  5,575
  5,924
  6,286
Revenue / Adjusted assets
  0.946
  0.951
  0.947
  0.950
  0.950
  0.949
  0.949
  0.950
  0.950
  0.949
  0.949
  0.948
  0.949
  0.949
  0.949
  0.949
  0.949
  0.949
  0.949
  0.949
  0.949
  0.949
  0.949
  0.949
  0.949
  0.949
  0.949
  0.949
  0.949
  0.949
Average production assets, $m
  4
  5
  6
  7
  9
  11
  13
  15
  17
  19
  22
  25
  28
  31
  34
  37
  41
  44
  48
  52
  56
  61
  65
  70
  74
  79
  85
  90
  96
  101
Working capital, $m
  -130
  -164
  -204
  -249
  -300
  -358
  -421
  -490
  -564
  -644
  -730
  -821
  -917
  -1,019
  -1,125
  -1,237
  -1,353
  -1,474
  -1,601
  -1,732
  -1,869
  -2,011
  -2,159
  -2,312
  -2,472
  -2,638
  -2,810
  -2,989
  -3,176
  -3,371
Total debt, $m
  -24
  33
  100
  176
  262
  358
  464
  580
  705
  840
  984
  1,137
  1,298
  1,468
  1,647
  1,834
  2,029
  2,233
  2,445
  2,666
  2,895
  3,134
  3,382
  3,640
  3,907
  4,186
  4,475
  4,776
  5,090
  5,416
Total liabilities, $m
  217
  275
  342
  418
  504
  600
  706
  822
  947
  1,082
  1,226
  1,378
  1,540
  1,710
  1,889
  2,076
  2,271
  2,475
  2,687
  2,908
  3,137
  3,376
  3,624
  3,881
  4,149
  4,427
  4,717
  5,018
  5,331
  5,658
Total equity, $m
  24
  31
  38
  46
  56
  67
  78
  91
  105
  120
  136
  153
  171
  190
  210
  231
  252
  275
  299
  323
  349
  375
  403
  431
  461
  492
  524
  558
  592
  629
Total liabilities and equity, $m
  241
  306
  380
  464
  560
  667
  784
  913
  1,052
  1,202
  1,362
  1,531
  1,711
  1,900
  2,099
  2,307
  2,523
  2,750
  2,986
  3,231
  3,486
  3,751
  4,027
  4,312
  4,610
  4,919
  5,241
  5,576
  5,923
  6,287
Debt-to-equity ratio
  -1.000
  1.090
  2.630
  3.800
  4.690
  5.380
  5.920
  6.350
  6.700
  6.990
  7.230
  7.420
  7.590
  7.730
  7.850
  7.950
  8.040
  8.120
  8.190
  8.250
  8.310
  8.360
  8.400
  8.440
  8.480
  8.510
  8.540
  8.570
  8.590
  8.620
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -4,007
  -5,036
  -6,236
  -7,609
  -9,158
  -10,885
  -12,789
  -14,868
  -17,120
  -19,541
  -22,125
  -24,872
  -27,775
  -30,833
  -34,043
  -37,403
  -40,913
  -44,573
  -48,385
  -52,352
  -56,476
  -60,762
  -65,216
  -69,845
  -74,656
  -79,657
  -84,857
  -90,267
  -95,897
  -101,760
Depreciation, amort., depletion, $m
  1
  1
  2
  2
  2
  3
  3
  3
  4
  4
  4
  5
  6
  6
  7
  7
  8
  9
  10
  10
  11
  12
  13
  14
  15
  16
  17
  18
  19
  20
Funds from operations, $m
  -4,006
  -5,035
  -6,235
  -7,607
  -9,156
  -10,883
  -12,786
  -14,865
  -17,116
  -19,536
  -22,121
  -24,867
  -27,770
  -30,827
  -34,036
  -37,396
  -40,905
  -44,564
  -48,376
  -52,341
  -56,464
  -60,750
  -65,203
  -69,831
  -74,641
  -79,641
  -84,840
  -90,249
  -95,878
  -101,740
Change in working capital, $m
  -29
  -34
  -40
  -45
  -51
  -57
  -63
  -69
  -75
  -80
  -86
  -91
  -96
  -101
  -106
  -111
  -116
  -121
  -126
  -132
  -137
  -142
  -148
  -153
  -160
  -166
  -172
  -179
  -187
  -194
Cash from operations, $m
  -3,977
  -5,001
  -6,195
  -7,562
  -9,105
  -10,825
  -12,723
  -14,796
  -17,042
  -19,456
  -22,035
  -24,776
  -27,673
  -30,726
  -33,930
  -37,284
  -40,789
  -44,443
  -48,249
  -52,210
  -56,328
  -60,608
  -65,056
  -69,678
  -74,481
  -79,475
  -84,668
  -90,070
  -95,692
  -101,546
Maintenance CAPEX, $m
  -1
  -1
  -1
  -1
  -1
  -2
  -2
  -3
  -3
  -3
  -4
  -4
  -5
  -6
  -6
  -7
  -7
  -8
  -9
  -10
  -10
  -11
  -12
  -13
  -14
  -15
  -16
  -17
  -18
  -19
New CAPEX, $m
  -1
  -1
  -1
  -1
  -2
  -2
  -2
  -2
  -2
  -2
  -3
  -3
  -3
  -3
  -3
  -3
  -4
  -4
  -4
  -4
  -4
  -4
  -4
  -5
  -5
  -5
  -5
  -5
  -6
  -6
Cash from investing activities, $m
  -2
  -2
  -2
  -2
  -3
  -4
  -4
  -5
  -5
  -5
  -7
  -7
  -8
  -9
  -9
  -10
  -11
  -12
  -13
  -14
  -14
  -15
  -16
  -18
  -19
  -20
  -21
  -22
  -24
  -25
Free cash flow, $m
  -3,978
  -5,002
  -6,197
  -7,565
  -9,108
  -10,829
  -12,727
  -14,801
  -17,047
  -19,462
  -22,042
  -24,783
  -27,681
  -30,734
  -33,939
  -37,294
  -40,799
  -44,455
  -48,262
  -52,223
  -56,342
  -60,623
  -65,072
  -69,695
  -74,500
  -79,495
  -84,689
  -90,092
  -95,715
  -101,571
Issuance/(repayment) of debt, $m
  -24
  57
  67
  76
  86
  96
  106
  116
  125
  135
  144
  153
  162
  170
  179
  187
  195
  204
  212
  221
  230
  239
  248
  258
  268
  278
  289
  301
  313
  326
Issuance/(repurchase) of shares, $m
  4,085
  5,043
  6,244
  7,618
  9,168
  10,896
  12,801
  14,881
  17,134
  19,555
  22,141
  24,889
  27,793
  30,852
  34,063
  37,424
  40,935
  44,596
  48,409
  52,376
  56,501
  60,788
  65,244
  69,874
  74,685
  79,687
  84,889
  90,300
  95,932
  101,797
Cash from financing (excl. dividends), $m  
  4,061
  5,100
  6,311
  7,694
  9,254
  10,992
  12,907
  14,997
  17,259
  19,690
  22,285
  25,042
  27,955
  31,022
  34,242
  37,611
  41,130
  44,800
  48,621
  52,597
  56,731
  61,027
  65,492
  70,132
  74,953
  79,965
  85,178
  90,601
  96,245
  102,123
Total cash flow (excl. dividends), $m
  82
  98
  113
  130
  146
  163
  180
  196
  212
  228
  243
  259
  273
  288
  302
  316
  331
  345
  359
  374
  388
  404
  420
  436
  453
  471
  490
  510
  530
  552
Retained Cash Flow (-), $m
  -4,085
  -5,043
  -6,244
  -7,618
  -9,168
  -10,896
  -12,801
  -14,881
  -17,134
  -19,555
  -22,141
  -24,889
  -27,793
  -30,852
  -34,063
  -37,424
  -40,935
  -44,596
  -48,409
  -52,376
  -56,501
  -60,788
  -65,244
  -69,874
  -74,685
  -79,687
  -84,889
  -90,300
  -95,932
  -101,797
Prev. year cash balance distribution, $m
  177
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  -3,826
  -4,945
  -6,131
  -7,488
  -9,022
  -10,733
  -12,621
  -14,685
  -16,922
  -19,327
  -21,898
  -24,630
  -27,520
  -30,564
  -33,760
  -37,107
  -40,604
  -44,251
  -48,050
  -52,002
  -56,113
  -60,385
  -64,824
  -69,438
  -74,232
  -79,216
  -84,399
  -89,791
  -95,402
  -101,244
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  -3,668
  -4,527
  -5,335
  -6,166
  -6,993
  -7,789
  -8,527
  -9,179
  -9,721
  -10,132
  -10,399
  -10,511
  -10,464
  -10,261
  -9,911
  -9,430
  -8,835
  -8,149
  -7,398
  -6,608
  -5,804
  -5,010
  -4,249
  -3,537
  -2,888
  -2,311
  -1,811
  -1,389
  -1,041
  -762
Current shareholders' claim on cash, %
  50.0
  0.9
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company's lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD). It is involved in developing vadadustat as an oral therapy. The Company's vadadustat is a HIF-prolyl-hydroxylase (HIF-PH) inhibitor in Phase III development for the treatment of anemia of CKD. In addition to vadadustat, the Company is engaged in developing a HIF-based portfolio of product candidates that target serious diseases of unmet need. Its portfolio includes product candidates developed internally, such as AKB-6899, as well as in-licensed product candidates, including AKB-5169. AKB-5169 is a preclinical compound in development as an oral treatment for inflammatory bowel disease (IBD).

FINANCIAL RATIOS  of  Akebia Therapeutics, Inc. (AKBA)

Valuation Ratios
P/E Ratio -1.2
Price to Sales 79.2
Price to Book 2.3
Price to Tangible Book
Price to Cash Flow 2.7
Price to Free Cash Flow 2.9
Growth Rates
Sales Growth Rate -100%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate NaN%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets -61.4%
Ret/ On Assets - 3 Yr. Avg. -53.4%
Return On Total Capital -136.7%
Ret/ On T. Cap. - 3 Yr. Avg. -81.1%
Return On Equity -136.7%
Return On Equity - 3 Yr. Avg. -81.1%
Asset Turnover 0
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin -6800%
EBITDA Margin - 3 Yr. Avg. -2266.7%
Operating Margin -6800%
Oper. Margin - 3 Yr. Avg. -2266.7%
Pre-Tax Margin -6800%
Pre-Tax Margin - 3 Yr. Avg. -2266.7%
Net Profit Margin -6800%
Net Profit Margin - 3 Yr. Avg. -2266.7%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

AKBA stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the AKBA stock intrinsic value calculation we used $178 million for the last fiscal year's total revenue generated by Akebia Therapeutics, Inc.. The default revenue input number comes from 0001 income statement of Akebia Therapeutics, Inc.. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our AKBA stock valuation model: a) initial revenue growth rate of 28.8% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for AKBA is calculated based on our internal credit rating of Akebia Therapeutics, Inc., is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Akebia Therapeutics, Inc..
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of AKBA stock the variable cost ratio is equal to 1797.8%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $112 million in the base year in the intrinsic value calculation for AKBA stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Akebia Therapeutics, Inc..

Corporate tax rate of 27% is the nominal tax rate for Akebia Therapeutics, Inc.. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the AKBA stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for AKBA are equal to 1.7%.

Life of production assets of 5 years is the average useful life of capital assets used in Akebia Therapeutics, Inc. operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for AKBA is equal to -56.5%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $122.574 million for Akebia Therapeutics, Inc. - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 116.887 million for Akebia Therapeutics, Inc. is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Akebia Therapeutics, Inc. at the current share price and the inputted number of shares is $0.5 billion.

RELATED COMPANIES Price Int.Val. Rating
FGEN FibroGen, Inc 40.68 130.70  str.buy
ARDX Ardelyx, Inc. 2.66 0.46  str.sell
PIRS Pieris Pharmac 4.33 10.45  str.buy
JNJ Johnson & John 140.09 107.87  sell
AMGN Amgen Inc. 176.08 157.83  hold

CONTACT US      

About X-FIN       Privacy policy       Terms of use      

Copyright © X-FIN.com 2005-2019. All rigths reserved.